Abstract: Anti-CD133 monoclonal antibodies having advantageous properties, products, compositions and kits comprising the monoclonal antibodies, methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.

Abstract: A three-dimensional heterogenous cell spheroid comprising a plurality of at least two different types of cells and one or more short peptide cell linkers. The peptide cell linkers are linear peptides having respective terminal ends, and comprising an adhesion sequence at or near each end, with a suitable spacer sequence between each adhesion sequence. Methods of making and using such spheroids for in vitro testing are also described.

Abstract: Anti-CD133 monoclonal antibodies having advantageous properties, products, compositions and kits comprising the monoclonal antibodies, methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.

Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.

Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.

Abstract: Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.

Abstract: The present invention provides a set of methods and compositions for homogeneous coupled luminescent assays of cytotoxicity and/or proliferation of cells, as well as for enzymatic activity. In both cases the activities of the enzymes of interest are coupled to production of a high-energy molecule, which serves as a substrate for the production of light by a luciferase, typically in a single reagent mixture, with a useful readout available in 1—5 minutes. Individual cytotoxicity and proliferation signals can be measured from a single sample in 6 minutes or less. The invention also provides a 3-minute, one-step phosphatase assay. The ability to couple the activity of interest to light production in a one-step procedure gives rise to extremely rapid and flexible methods for measurement of cytotoxic effects and enzymatic activities. The assay methods are highly suitable for use in high-throughput screening procedures.

Abstract: Methods of screening for and/or detecting the presence or absence of cancers or treating cancers are described. In an aspect of the present invention, the screening methods are based on the detection of the PAL-18 protein, variants thereof, or a nucleic acid molecules encoding the same, found to be associated with the presence of cancer. Additional methods for imaging using antibodies for PAL-18 or modulating PAL-18 are provided. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen (e.g., PAL-18) based on nucleic acid amplification.

Abstract: Methods of screening for cancers or treating cancers or autoimmune disorders are disclosed. In an aspect of the present invention, the screening methods are based on the detection of complement C3 or C3 related protein, or a nucleic acid molecule encoding the same, found to be associated with the presence of cancer. Additional screening methods are based on the use of complement regulators Factor I or DAF, or complement receptors 1 or 3. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen based on nucleic acid amplification.

Abstract: Methods of screening for cancers or treating cancers or autoimmune disorders are disclosed. In an aspect of the present invention, the screening methods are based on the detection of complement C3 or C3 related protein, or a nucleic acid molecule encoding the same, found to be associated with the presence of cancer. Additional screening methods are based on the use of complement regulators Factor I or DAF, or complement receptors 1 or 3. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen based on nucleic acid amplification.

Abstract: Methods of screening for or treating cancer are disclosed. The screening methods are based on the detection of an antigen, or a nucleic acid molecule encoding the antigen, found by the present invention to be associated with the presence of cancer. Preferred embodiments of the methods include detection of the antigen based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding the antigen based on nucleic acid amplification.